Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles.
Polycationic molecules form condensates with DNA and are used for gene therapy as an alternative to viral vectors. As clinical efficacy corresponds to cellular uptake, intracellular stability of the condensates, and bioavailability of the DNA, it is crucial to analyze uptake mechanisms and trafficking pathways. Here, a detailed study of uptake, stability, and localization of PLL-g-PEG-DNA nanoparticles within COS-7 cells is presented, using FACS analysis to assess the involvement of different uptake mechanisms, colocalization studies with markers indicative for different endocytotic pathways, and immunofluorescence staining to analyze colocalization with intracellular compartments. PLL-g-PEG-DNA nanoparticles were internalized in an energy-dependent manner after 2 h and accumulated in the perinuclear region after >6 h. The nanoparticles were found to be stable within the cytoplasm for at least 24 h and did not colocalize with the endosomal pathway. Nanoparticle uptake was approximately 50% inhibited by genistein, an inhibitor of the caveolae-mediated pathway. However, genistein did not inhibit gene expression, and PLL-g-PEG-DNA nanoparticles were not colocalized with caveolin-1 indicating that caveolae-mediated endocytosis is not decisive for DNA delivery. Clathrin-mediated endocytosis and macropinocytosis pathways were reduced by 17 and 24%, respectively, in the presence of the respective inhibitors. When cells were transfected in the presence of double and triple inhibitors, transfection efficiencies were increasingly reduced by 40 and 70%, respectively; however, no differences were found between the different uptake mechanisms. These findings suggest that PLL-g-PEG-DNA nanoparticles enter by several pathways and might therefore be an efficient and versatile tool to deliver therapeutic DNA.
Lühmann
Tessa
T
Department of Materials, ETH Zurich, Zurich, Switzerland.
Rimann
Markus
M
Bittermann
Anne Greet
AG
Hall
Heike
H
D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D002966:Clathrin / Q000378:metabolism; D003593:Cytoplasm / Q000737:chemistry / Q000378:metabolism*; D004247:DNA / Q000737:chemistry* / Q000378:metabolism; D004705:Endocytosis / Q000502:physiology*; D005455:Fluorescent Antibody Technique / Q000379:methods; D005456:Fluorescent Dyes / Q000737:chemistry; D015316:Genetic Therapy / Q000379:methods*; D019833:Genistein / Q000494:pharmacology; D053758:Nanoparticles / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000138:chemical synthesis* / Q000378:metabolism; D011107:Polylysine / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D013997:Time Factors
D002966:Clathrin; D005456:Fluorescent Dyes; D047428:Protein Kinase Inhibitors; D011107:Polylysine; D011092:Polyethylene Glycols; D004247:DNA; D019833:Genistein